Return to homepagePandemic Pact

Coronavirus SARS-CoV-2 Antibody Estonian Seroprevalence Survey in Estonia

Grant number: LMVBS20513

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $151,563.93

  • Funder

    Estonian Research Council

  • Principal Investigator

    Irja Lutsar

  • Research Location

    Estonia

  • Lead Research Institution

    University of Tartu, Department of Medical Sciences, Institute of Biomedical and Transitional Medicine

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

As a result of the KoroSero-EST-1 study, it was found that the seroprevalence of SARS-CoV-2 in Saaremaa was about 6 percent and in Tallinn about 1.5%, but 80% of SARS-CoV-2 seropositives were asymptomatic. These individuals form an important group in understanding SARS-CoV-2 infection and its spread, as it is still unclear why the infection goes unnoticed in some individuals. A follow-up study of KoroSero-EST-1 will investigate whether asymptomatic individuals have developed immune memory for antibodies and T-cell immunity, compare it to patients with mild and severe COVID-19, and determine whether individuals with varying degrees of disease have different levels of inflammatory markers. In addition, it is examined whether the genetic background of these individuals is different.